Status:
ACTIVE_NOT_RECRUITING
Reversibility of Methacholine Induced Bronchoconstriction
Lead Sponsor:
University of Saskatchewan
Conditions:
Asthma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The study will compare salbutamol reversibility of methacholine induced bronchoconstriction between a pressurized metered dose inhaler with a spacer versus nebulizer administration using a vibrating m...
Eligibility Criteria
Inclusion
- age (years) at least 18, male or female
- no confounding health issue (i.e. no health conditions, other than asthma, that would put the participant at risk or affect data integrity)
- baseline FEV1 ≥ 65% predicted (per Quanjer GLI 2012)
- methacholine PD20 ≤ 800mcg
Exclusion
- respiratory infection within 4 weeks of Visit 1
- exposure to triggers of respiratory symptoms within 4 weeks of Visit 1
- currently pregnant or breastfeeding
- current smoker (cigarettes, vaping)
Key Trial Info
Start Date :
January 12 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05977699
Start Date
January 12 2024
End Date
December 30 2024
Last Update
December 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asthma Research Lab University of Saskatchewan Room 346 Ellis Hall
Saskatoon, Saskatchewan, Canada, S7N 0W8